Table 1.

Basic characteristics of patients who met the inclusion criteria

	Patients initiated on remdesivir (n = 824)	Patients without remdesivir (n = 11,663)	Total (n = 12,487)
Age (years)	68 [56–79]	51 [34–71]	52 [35–71]
Male	532 (64.6%)	6,176 (53.0%)	6,708 (53.7%)
Cardiovascular disease	57 (6.9%)	547 (4.7%)	604 (4.8%)
Respiratory disease	34 (4.1%)	268 (2.3%)	302 (2.4%)
Diabetes mellitus	225 (27.3%)	1,415 (12.1%)	1,640 (13.1%)
Severe renal disease or dialysis	19 (2.3%)	200 (1.7%)	219 (1.8%)
Hypertension	367 (44.5%)	2,845 (24.4%)	3,212 (25.7%)
Obesity	90 (10.9%)	809 (6.9%)	899 (7.2%)
Charlson Comorbidity Index	1 [0–2]	0 [0–1]	0 [0–1]
NEWS at Day 1	1 [0–2]	1 [0–2]	1 [0–2]
NEWS at Day 4	2 [1–4]	1 [0–2]	1 [0–2]
NEWS at Day 8	2 [1–4]	1 [0–2]	1 [0–2]
NEWS at Day 15	2 [1–4]	1 [0–2]	1 [0–3]
NEWS at Day 22	3 [1–5]	1 [0–3]	1 [0–3]
NEWS at Day 29	11 [9–13]	9 [9–11]	9 [9–11]
Fatal cases	69 (8.4%)	285 (2.4%)	354 (2.8%)
Oxygen administration during hospitalization*	559 (67.8%)	1,784 (15.3%)	2,343 (18.8%)
IMV/ECMO during hospitalization	48 (5.8%)	98 (0.8%)	146 (1.2%)
Days from symptom onset to hospitalization	3 [1–4]	3 [1–4]	3 [1–4]
Use of systemic steroids	666 (80.8%)	1,840 (15.8%)	2,506 (20.1%)
Use of favipiravir	264 (32.0%)	2,926 (25.1%)	3,190 (25.5%)
Use of tocilizumab	63 (7.7%)	100 (0.9%)	163 (1.3%)
Use of baricitinib	0 (0%)	0 (0%)	0 (0%)
Days from onset to remdesivir administration	6 [4–9]	NA	NA
Days from admission to remdesivir administration	5 [3–10]	NA	NA
Duration of remdesivir administration 5 days	485 (58.9%)	NA	NA

Numbers in brackets represent percentage and interquartile range.

NA = not available; NEWS = national early warning score; IMV/ECMO = invasive mechanical ventilation/extracorporeal membrane oxygenation.

^⁎Indication for supplementary oxygen was judged by each physician.